참고문헌
- Kyle R A, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-1873. https://doi.org/10.1056/NEJMra041875
- Phekoo KJ, Schey SA, Richards MA, et al. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol 2004;127:299-304. https://doi.org/10.1111/j.1365-2141.2004.05207.x
- Kim HJ, Heo DS, Bang YJ, et al. Multiple myeloma in Korea: clinical analysis and treatment results in 61 cases. Korean J Intern Med 1987;2:120-124.
- Lee JH, Bang SM. Epidemiological change of multiple myeloma in Korea. Korean J Hematol 2006;41:225-234. https://doi.org/10.5045/kjh.2006.41.4.225
- Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825-831. https://doi.org/10.1016/S0140-6736(06)68338-4
- Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009;27:3664-3670. https://doi.org/10.1200/JCO.2008.21.0948
- Wijermans P, Schaafsma M, Termorshuizen F, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol 2010;28:3160-3166. https://doi.org/10.1200/JCO.2009.26.1610
- Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced- intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370:1209-1218. https://doi.org/10.1016/S0140-6736(07)61537-2
- Yakoub-Agha I, Attal M, Dumontet C, et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients- -report of the Intergroupe Francophone du Myelome (IFM). Hematol J 2002;3:185-192. https://doi.org/10.1038/sj.thj.6200175
- Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: intergroupe Francais du Myelome. N Engl J Med 1996;335:91-97. https://doi.org/10.1056/NEJM199607113350204
- Qazilbash MH, Saliba RM, Hosing C, et al. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 2007;39:279-283. https://doi.org/10.1038/sj.bmt.1705580
- Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol 1998;16:3832-3842. https://doi.org/10.1200/JCO.1998.16.12.3832
- Waage A, Gimsing P, Fayers P, et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 2010;116:1405-1412. https://doi.org/10.1182/blood-2009-08-237974
- Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-1571. https://doi.org/10.1056/NEJM199911183412102
- Hus I, Dmoszynska A, Manko J, et al. An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma. Br J Cancer 2004;91:1873-1879. https://doi.org/10.1038/sj.bjc.6602225
- Steurer M, Spizzo G, Mitterer M, Gastl G. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program. Onkologie 2004;27:150-154. https://doi.org/10.1159/000076904
- Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009;114:3139-3146. https://doi.org/10.1182/blood-2009-03-201053
- El Accaoui RN, Shamseddeen WA, Taher AT. Thalidomide and thrombosis: a meta-analysis. Thromb Haemost 2007;97:1031-1036.
- Koh Y, Bang SM, Lee JH, et al. Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. Ann Hematol 2010;89:201-206. https://doi.org/10.1007/s00277-009-0807-6
- San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-917. https://doi.org/10.1056/NEJMoa0801479
- Zonder JA, Crowley J, Hussein MA, et al. Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebocontrolled SWOG trial S0232. Blood 2007;110:77.
피인용 문헌
- Is the Low-Thalidomide Dose MPT Regimen Beneficial? vol.26, pp.4, 2011, https://doi.org/10.3904/kjim.2011.26.4.400